Background: Multiple myeloma that is refractory to proteasome inhibitors and immunomodulatory agents has a very poor prognosis. Therapies in this setting included XPO-1 inhibitor Selinexor and anti-BCMA bispecific antibody belantamab mafadotin which have modest, at best, response rates <35% and median PFS of <6 months. CAR-T cell therapy targeting B-cel…
Keep reading with a 7-day free trial
Subscribe to Hematology Oncology Snippets to keep reading this post and get 7 days of free access to the full post archives.